GSK Touts 42% Survival Benefit for Blenrep in Multiple Myeloma, Strengthening Bid for Market Return
The overall survival edge over J&J’s Darzalex will help GSK strengthen its case as it plots the market comeback of Blenrep, which was pulled after a failed confirmatory study.
